RESET-SLE: CAR T-Cell Therapy for Lupus

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Systemic Lupus Erythematosus

a study on Lupus CAR T-Cell Therapy Autoimmune Disease

Summary

Eligibility
for people ages 18-65 (full criteria)
Location
at UC Davis UC Irvine
Dates
study started
study ends around
Principal Investigator
by Priyanka Iyer, MD (uci)Gaurav Gulati, MD (ucdavis)
Headshot of Priyanka Iyer
Priyanka Iyer
Headshot of Gaurav Gulati
Gaurav Gulati

Description

Summary

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Official Title

A Phase 1/2, Open-label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Systemic Lupus Erythematosus

Details

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by autoantibody production and abnormal B cell function. SLE presents with fluctuating severity and may cause tissue damage in a variety of organs over time. Lupus nephritis (LN) (renal involvement) is a common severe manifestation of SLE, which can lead to significant morbidity and mortality. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, also called resecabtagene autoleucel, or "rese-cel". Rese-cel can be given to patients with either LN or SLE without renal involvement, in two separate parallel cohorts, who have active disease. Initially a single dose of CABA-201 in patients pretreated with a standard regimen including cyclophosphamide (CY) and fludarabine (FLU), will be evaluated. In addition, escalating doses of CABA-201 will be evaluated in patients without CY and FLU pretreatment.

Keywords

Systemic Lupus Erythematosus, Lupus Nephritis, CABA-201, Autoimmune Disease, Anti-CD19 CAR-T therapy, Cellular Therapy, Autoimmune Diseases

Eligibility

You can join if…

Open to people ages 18-65

  • Age ≥18 and ≤65
  • A clinical diagnosis of SLE, based on the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for adult SLE.
  • Positive antinuclear antibody (ANA) titer or anti-dsDNA antibody at screening.
  • For LN subjects only, active, biopsy-proven LN class III or IV, with or without the presence of class V, according to 2018 Revised International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria
  • For non-renal SLE subjects only: Active, moderate to severe SLE

You CAN'T join if...

  • Contraindication to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
  • For LN subjects only: The presence of kidney disease other than active lupus nephritis
  • Previous CAR T cell therapy
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant.

Locations

  • University of California Irvine accepting new patients
    Orange California 92868 United States
  • UC Davis Health accepting new patients
    Sacramento California 95817 United States

Lead Scientists at University of California Health

  • Priyanka Iyer, MD (uci)
    Assistant Health Sciences Professor, Medicine, School of Medicine
  • Gaurav Gulati, MD (ucdavis)
    Associate Professor of Clinical, MED: Int Med Rheumatology, School of Medicine. Authored (or co-authored) 8 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Cabaletta Bio
ID
NCT06121297
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 28 study participants
Last Updated
Contact us about this trial